Celldex Therapeutics, Inc. · NASDAQ:CLDX

Vanguard Capital Management LLC reported a 5.17% stake in Celldex Therapeutics, Inc. (Schedule 13G)

Event Mar 31, 2026 · Filed Apr 29, 2026

Vanguard Capital Management LLC reported a 5.17% stake in Celldex Therapeutics, Inc., 3,446,795 shares, as a passive investor on Mar 31, 2026. Filed Apr 29, 2026 (Schedule 13G).

Stake
5.17%
Shares
3,446,795
Intent
Passive
What changed
Crossed above 5%

The filing in full

HolderStakeShares
Vanguard Capital Management5.17%3,446,795

Source

View original at SEC

Related